Advertisement: Birketts mid banner
Advertisement: cofinitive mid banner
Advertisement: Allia mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Featurespace mid banner
Advertisement: Ilux mid banner
Advertisement: Evelyn mid banner
Advertisement: Arm mid banner
Advertisement: CambridgeTechPodcast midbanner
Advertisement: Cambridge Network mid banner
Cambridgeand mid banner advertisement
Advertisement: Wild Knight Vodka
Advertisement: Alan Boswell Group mid banner
Advertisement: SATAVIA mid banner
Advertisement mid banner S-Tech 3
Advertisement: Mogrify mid banner
Barr Ellison Solicitors – commercial property
Advertisement: TTP
Advertisement: CJBS mid banner
Advertisement: SJIP Dirac Building mid-banner
Advertisement: RSM mid banner
Advertisement: Shearline mid banner
Mid banner advertisement: BDO
Advertisement: Simpsons Creative mid banner
Advertisement: SourceBioscience mid banner
Advertisement: Bicycle mid banner
Advertisement: Marshall mid banner
15 July, 2023 - 22:14 By News Desk

Mestag – signalling a new era in immunotherapy

Mestag is an immunotherapy company harnessing new insights into fibroblast-immune cell interactions to develop innovative treatments for cancer and inflammatory diseases. 

Through our unique understanding of fibroblast biology, we are advancing a pipeline of first-in-class tailored antibody programs and exploring innovative targets for new treatments.

We’re building on the work of a group of inspirational founders who are leaders in the field and we’re backed by transatlantic investors SV Health, Johnson & Johnson Innovation, GV, Forbion and Northpond, raising $45 million in our seed funding round. 

Activated fibroblasts in disease

Discoveries made by our founders and other researchers show that fibroblasts – cells long known for their structural role in both health and disease – also have a far-reaching influence on the primary players of the immune system, including T cells, B cells, dendritic cells and macrophages.

We’re developing new treatments that modulate these fibroblast-driven immune conversations, with the goal of increasing anti-cancer immune activity in the tumour microenvironment or diminishing the overactive immune response in inflammatory diseases.

Fibroblast-immune interactions are implicated as drivers of disease in multiple solid tumours, rheumatoid arthritis, scleroderma, inflammatory bowel disease, lupus and Sjögren’s.

Advancing therapies to patients

Our activities are underpinned by highly specialist data analytics, complex tissue assays, human tissue focus and a deep understanding of antibody engineering. 

We have a target discovery collaboration with Janssen Biotech, Inc which leverages Mestag’s specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets. 

We also partner extensively with academic institutions worldwide and with leading CROs, and recently signed an agreement with VIB, the leading European research institute, to research, develop and commercialise a panel of single domain antibodies, also known as Nanobodies®, in oncology.

A great place to work

Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.

We are based in spacious and modern laboratory and office facilities at Chesterford Research Park. Our facilities are kitted out with state-of-the-art instruments to enable our dedicated researchers to deliver incredible science. 

We have access to a range of onsite facilities including a gym, canteen, golf course, free parking and even a local pub at the bottom of the road for after work down time.

• To check out current vacancies and find out more about us, visit our website

Newsletter Subscription

Stay informed of the latest news and features